Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

MicroRNAs Affect Complement Regulator Expression and Mitochondrial Activity to Modulate Cell Resistance to Complement-Dependent Cytotoxicity.

Hillman Y, Mardamshina M, Pasmanik-Chor M, Ziporen L, Geiger T, Shomron N, Fishelson Z.

Cancer Immunol Res. 2019 Dec;7(12):1970-1983. doi: 10.1158/2326-6066.CIR-18-0818. Epub 2019 Sep 19.

PMID:
31537542
2.

Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.

Fishelson Z, Kirschfink M.

Front Immunol. 2019 Apr 10;10:752. doi: 10.3389/fimmu.2019.00752. eCollection 2019. Review.

3.

Receptor-Interacting Protein Kinases 1 and 3, and Mixed Lineage Kinase Domain-Like Protein Are Activated by Sublytic Complement and Participate in Complement-Dependent Cytotoxicity.

Lusthaus M, Mazkereth N, Donin N, Fishelson Z.

Front Immunol. 2018 Feb 23;9:306. doi: 10.3389/fimmu.2018.00306. eCollection 2018.

4.

Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.

Rozenberg P, Ziporen L, Gancz D, Saar-Ray M, Fishelson Z.

Cell Death Dis. 2018 Feb 2;9(2):150. doi: 10.1038/s41419-017-0240-z.

5.

Circulating mitochondrial stress 70 protein/mortalin and cytosolic Hsp70 in blood: Risk indicators in colorectal cancer.

Jubran R, Kocsis J, Garam N, Maláti É, Gombos T, Barabás L, Gráf L, Prohászka Z, Fishelson Z.

Int J Cancer. 2017 Dec 1;141(11):2329-2335. doi: 10.1002/ijc.30918. Epub 2017 Aug 21.

6.

Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane.

Mazkereth N, Rocca F, Schubert JR, Geisler C, Hillman Y, Egner A, Fishelson Z.

Immunobiology. 2016 Dec;221(12):1395-1406. doi: 10.1016/j.imbio.2016.07.005. Epub 2016 Jul 21.

PMID:
27475989
7.

Astrocytes from old Alzheimer's disease mice are impaired in Aβ uptake and in neuroprotection.

Iram T, Trudler D, Kain D, Kanner S, Galron R, Vassar R, Barzilai A, Blinder P, Fishelson Z, Frenkel D.

Neurobiol Dis. 2016 Dec;96:84-94. doi: 10.1016/j.nbd.2016.08.001. Epub 2016 Aug 17.

PMID:
27544484
8.

Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.

Hillman Y, Mazkereth N, Farberov L, Shomron N, Fishelson Z.

J Immunol. 2016 Jun 15;196(12):5156-65. doi: 10.4049/jimmunol.1502701. Epub 2016 May 4.

9.

Complement nomenclature 2014.

Kemper C, Pangburn MK, Fishelson Z.

Mol Immunol. 2014 Oct;61(2):56-8. doi: 10.1016/j.molimm.2014.07.004. Epub 2014 Jul 28. Review.

PMID:
25081089
10.

Preface to the special issue for the XXV International Complement Workshop.

Tambourgi DV, Fishelson Z.

Mol Immunol. 2014 Oct;61(2):55. doi: 10.1016/j.molimm.2014.07.002. Epub 2014 Jul 22. No abstract available.

PMID:
25062834
11.

Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity.

Saar Ray M, Moskovich O, Iosefson O, Fishelson Z.

J Biol Chem. 2014 May 23;289(21):15014-22. doi: 10.1074/jbc.M114.552406. Epub 2014 Apr 9.

12.

Quantification of complement C5b-9 binding to cells by flow cytometry.

Moskovich O, Fishelson Z.

Methods Mol Biol. 2014;1100:103-8. doi: 10.1007/978-1-62703-724-2_8.

PMID:
24218253
13.

Construction and characterization of recombinant human C9 or C7 linked to single chain Fv directed to CD25.

Raitses Gurevich M, Fishelson Z.

Mol Immunol. 2013 Oct;55(3-4):400-8. doi: 10.1016/j.molimm.2013.03.013. Epub 2013 Apr 10.

PMID:
23582305
14.

Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer.

Rozenberg P, Kocsis J, Saar M, Prohászka Z, Füst G, Fishelson Z.

Int J Cancer. 2013 Jul 15;133(2):514-8. doi: 10.1002/ijc.28029. Epub 2013 Feb 12.

15.

Clostridium difficile infection and partial membrane cofactor protein (CD46) deficiency.

Kalmanovich E, Kriger-Sharabi O, Shiloah E, Donin N, Fishelson Z, Rapoport MJ.

Isr Med Assoc J. 2012 Sep;14(9):586-7. No abstract available.

16.

A role for the NF-κB pathway in cell protection from complement-dependent cytotoxicity.

Gancz D, Lusthaus M, Fishelson Z.

J Immunol. 2012 Jul 15;189(2):860-6. doi: 10.4049/jimmunol.1103451. Epub 2012 Jun 8.

17.

Caveolin-1 and dynamin-2 are essential for removal of the complement C5b-9 complex via endocytosis.

Moskovich O, Herzog LO, Ehrlich M, Fishelson Z.

J Biol Chem. 2012 Jun 8;287(24):19904-15. doi: 10.1074/jbc.M111.333039. Epub 2012 Apr 23.

18.

A novel mutation in the C3 gene and recurrent invasive pneumococcal infection: a clue for vaccine development.

Goldberg M, Fremeaux-Bacchi V, Koch P, Fishelson Z, Katz Y.

Mol Immunol. 2011 Sep;48(15-16):1926-31. doi: 10.1016/j.molimm.2011.05.020. Epub 2011 Jun 15.

PMID:
21676463
19.

'Rejected' vs. 'rejecting' transcriptomes in allogeneic challenged colonial urochordates.

Oren M, Paz G, Douek J, Rosner A, Fishelson Z, Goulet TL, Henckel K, Rinkevich B.

Mol Immunol. 2010 Jul;47(11-12):2083-93. doi: 10.1016/j.molimm.2010.04.007. Epub 2010 May 7.

PMID:
20452026
20.

Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death.

Gancz D, Donin N, Fishelson Z.

Mol Immunol. 2009 Dec;47(2-3):310-7. doi: 10.1016/j.molimm.2009.09.016. Epub 2009 Oct 27.

PMID:
19864026
21.

Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.

Pilzer D, Saar M, Koya K, Fishelson Z.

Int J Cancer. 2010 Mar 15;126(6):1428-35. doi: 10.1002/ijc.24888.

22.

Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development.

Gancz D, Fishelson Z.

Mol Immunol. 2009 Sep;46(14):2794-800. doi: 10.1016/j.molimm.2009.05.009. Epub 2009 Jun 6. Review.

PMID:
19501402
23.

Programmed necrotic cell death induced by complement involves a Bid-dependent pathway.

Ziporen L, Donin N, Shmushkovich T, Gross A, Fishelson Z.

J Immunol. 2009 Jan 1;182(1):515-21.

24.

Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.

Odening KE, Li W, Rutz R, Laufs S, Fruehauf S, Fishelson Z, Kirschfink M.

Clin Exp Immunol. 2009 Feb;155(2):239-48. doi: 10.1111/j.1365-2249.2008.03817.x. Epub 2008 Nov 24.

25.

Urochordate histoincompatible interactions activate vertebrate-like coagulation system components.

Oren M, Escande ML, Paz G, Fishelson Z, Rinkevich B.

PLoS One. 2008 Sep 1;3(9):e3123. doi: 10.1371/journal.pone.0003123.

26.

Live cell imaging of outward and inward vesiculation induced by the complement c5b-9 complex.

Moskovich O, Fishelson Z.

J Biol Chem. 2007 Oct 12;282(41):29977-86. Epub 2007 Jul 20.

27.

Identification of immune-relevant genes in histoincompatible rejecting colonies of the tunicate Botryllus schlosseri.

Oren M, Douek J, Fishelson Z, Rinkevich B.

Dev Comp Immunol. 2007;31(9):889-902. Epub 2007 Jan 24.

PMID:
17287019
28.

Mapping of the complement C9 binding domain in paramyosin of the blood fluke Schistosoma mansoni.

Deng J, Gold D, LoVerde PT, Fishelson Z.

Int J Parasitol. 2007 Jan;37(1):67-75. Epub 2006 Oct 19.

PMID:
17123534
29.

Emission of membrane vesicles: roles in complement resistance, immunity and cancer.

Pilzer D, Gasser O, Moskovich O, Schifferli JA, Fishelson Z.

Springer Semin Immunopathol. 2005 Nov;27(3):375-87. Epub 2005 Nov 11. Review.

PMID:
16189651
30.
31.

Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysis.

Bohana-Kashtan O, Pinna LA, Fishelson Z.

Eur J Immunol. 2005 Jun;35(6):1939-48.

32.
33.

Schistosoma japonicum migration through mouse skin compared histologically and immunologically with S. mansoni.

Wang L, Li YL, Fishelson Z, Kusel JR, Ruppel A.

Parasitol Res. 2005 Feb;95(3):218-23. Epub 2005 Jan 27.

PMID:
15723270
34.

Increased sensitivity of early apoptotic cells to complement-mediated lysis.

Attali G, Gancz D, Fishelson Z.

Eur J Immunol. 2004 Nov;34(11):3236-45.

35.

Cell signals transduced by complement.

Bohana-Kashtan O, Ziporen L, Donin N, Kraus S, Fishelson Z.

Mol Immunol. 2004 Jul;41(6-7):583-97. Review.

PMID:
15219997
36.

Killing of schistosomes by elastase and hydrogen peroxide: implications for leukocyte-mediated schistosome killing.

Freudenstein-Dan A, Gold D, Fishelson Z.

J Parasitol. 2003 Dec;89(6):1129-35.

PMID:
14740899
37.

Inhibition of the complement membrane attack complex by Schistosoma mansoni paramyosin.

Deng J, Gold D, LoVerde PT, Fishelson Z.

Infect Immun. 2003 Nov;71(11):6402-10.

38.

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M.

Mol Immunol. 2003 Sep;40(2-4):109-23. Review.

PMID:
12914817
39.

Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z.

Clin Exp Immunol. 2003 Feb;131(2):254-63.

40.

Complement and apoptosis.

Fishelson Z, Attali G, Mevorach D.

Mol Immunol. 2001 Aug;38(2-3):207-19. Review.

PMID:
11532282
41.

K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.

Jurianz K, Ziegler S, Donin N, Reiter Y, Fishelson Z, Kirschfink M.

Int J Cancer. 2001 Sep;93(6):848-54.

42.

Contribution of heat shock proteins to cell protection from complement-mediated lysis.

Fishelson Z, Hochman I, Greene LE, Eisenberg E.

Int Immunol. 2001 Aug;13(8):983-91.

PMID:
11470768
43.
44.

Immunolocalization of the Toxin Latrunculin B within the Red Sea Sponge Negombata magnifica (Demospongiae, Latrunculiidae).

Gillor O, Carmeli S, Rahamim Y, Fishelson Z, Ilan M.

Mar Biotechnol (NY). 2000 May;2(3):213-23. doi: 10.1007/s101260000026.

PMID:
10852799
45.
46.

Complement resistance of tumor cells: basal and induced mechanisms.

Jurianz K, Ziegler S, Garcia-Schüler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M.

Mol Immunol. 1999 Sep-Oct;36(13-14):929-39. Review.

PMID:
10698347
47.

Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2.

Jurianz K, Maslak S, Garcia-Schüler H, Fishelson Z, Kirschfink M.

Immunopharmacology. 1999 May;42(1-3):209-18.

PMID:
10408382
48.

Phosphorylation of the complement component, C9, by an ecto-protein kinase of human leukemic cells.

Paas Y, Bohana-Kashtan O, Fishelson Z.

Immunopharmacology. 1999 May;42(1-3):175-85.

PMID:
10408378
49.

Distinction between processing of normal and mutant complement C3 within human skin fibroblasts.

Fishelson Z, Kozer E, Sirhan S, Katz Y.

Eur J Immunol. 1999 Mar;29(3):845-55.

50.

Supplemental Content

Loading ...
Support Center